Hansoh Pharmaceutical Group (HKG:3692) obtained clinical trial approval in China for HS-10529, according to a late Tuesday disclosure with the Hong Kong Exchange.
HS-10529 will be investigated as a treatment for advanced solid tumors, including pancreatic cancer, colorectal cancer, and non-small cell lung cancer with KRAS G12D mutations.
The stock slipped over 2% in afternoon trade on Wednesday.